SignalXSignalX

STOK Stoke Therapeutics, Inc.

8-K Current Report
Filed: March 3, 2026
Health Care
Pharmaceutical Preparations
Stoke Therapeutics, Inc. Overview

Stoke Therapeutics, Inc. (STOK) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 5.02: Departure/Election of Directors or Officers

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

  • • CEO Ian F. Smith awarded discretionary bonus of $697,125 for 2025 performance
  • • Bonus equals 100% of his target annual bonus, despite not participating in standard 2025 program
+2 more insights

Get deeper insights on Stoke Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.